Roflumilast Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:464383196
Width:240
Width2:240
Tradename:Daxas, Daliresp, Zoryve, others
Dailymedid:Roflumilast
Pregnancy Au:B3
Routes Of Administration:By mouth, topical
Class:PDE4 inhibitor
Atc Prefix:R03
Atc Suffix:DX07
Legal Au:S4
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Uk:POM
Legal Us:Rx-only
Legal Eu:Rx-only
Bioavailability:79%
Protein Bound:99%
Metabolism:Hepatic via CYP1A2 & CYP3A4
Elimination Half-Life:17 hours (30 hours [active metabolite])
Excretion:Urine (70%)
Cas Number:162401-32-3
Pubchem:449193
Iuphar Ligand:6962
Drugbank:DB01656
Chemspiderid:395793
Unii:0P6C6ZOP5U
Kegg:D05744
Chebi:47657
Chembl:193240
Pdb Ligand:ROF
Iupac Name:3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
C:17
H:14
Cl:2
F:2
N:2
O:3
Smiles:C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
Stdinchi:1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
Stdinchikey:MNDBXUUTURYVHR-UHFFFAOYSA-N

Roflumilast, sold under the brand name Daxas among others, is a medication used for the treatment of chronic obstructive pulmonary disease, plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. It acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects.[2] [3] [4]

It was approved for medical use in the European Union in 2010,[5] in the United States in 2011,[6] and in Canada in 2017.[7] It is available as a generic medication.[8]

Medical uses

Roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (COPD), plaque psoriasis,[9] [10] seborrheic dermatitis,[11] and atopic dermatitis,[12]

It is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (COPD).[13] [14] [15]

Adverse effects

Common (1–10% incidence) adverse effects include diarrhea, weight loss, nausea, headache, insomnia, decreased appetite, abdominal pain, rhinitis, sinusitis, urinary tract infection, and depression.[6] [13] [14] [15] [16]

Society and culture

Legal status

In June 2010, it was approved in the European Union for severe COPD associated with chronic bronchitis.[17] In February 2011, it gained FDA approval in the United States for reducing COPD exacerbations.[18] [19]

Further reading

Notes and References

  1. Web site: Zoryve Product information . . 7 November 2023 . 13 July 2024.
  2. Boswell-Smith V, Spina D . PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast . International Journal of Chronic Obstructive Pulmonary Disease . 2 . 2 . 121–9 . 2007 . 18044684 . 2695611 .
  3. Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK . Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma . Clinical and Experimental Allergy . 38 . 5 . 847–56 . May 2008 . 18307529 . 10.1111/j.1365-2222.2008.02950.x . 19050454 .
  4. Field SK . Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma . Expert Opinion on Investigational Drugs . 17 . 5 . 811–8 . May 2008 . 18447606 . 10.1517/13543784.17.5.811 . 73241684 .
  5. Web site: Daxas EPAR . . 17 September 2018 . 28 September 2020 . 12 August 2020 . https://web.archive.org/web/20200812193907/https://www.ema.europa.eu/en/medicines/human/EPAR/daxas . live .
  6. Web site: Daliresp- roflumilast tablet . DailyMed . 12 March 2020 . 28 September 2020 . 25 March 2021 . https://web.archive.org/web/20210325081719/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf . live .
  7. Web site: Daxas Product information . . 20 July 2017 . 13 July 2024.
  8. Web site: 2022 First Generic Drug Approvals . U.S. Food and Drug Administration (FDA) . 3 March 2023 . https://web.archive.org/web/20230630003602/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals . 30 June 2023 . live . 30 June 2023.
  9. Web site: Zoryve- roflumilast cream . DailyMed . 16 August 2022 . 21 January 2023 . 21 January 2023 . https://web.archive.org/web/20230121062229/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec1bb0d1-f38a-4080-831a-68791d1d1fdb . live .
  10. FDA Approves Arcutis' Zoryve (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older . Arcutis Biotherapeutics . GlobeNewswire . 29 July 2022 . 1 August 2022 . 1 August 2022 . https://web.archive.org/web/20220801114445/https://www.globenewswire.com/news-release/2022/07/29/2488966/0/en/FDA-Approves-Arcutis-ZORYVE-Roflumilast-Cream-0-3-For-the-Treatment-of-Plaque-Psoriasis-in-Individuals-Age-12-and-Older.html . live .
  11. Web site: Zoryve- roflumilast aerosol, foam . DailyMed . 20 December 2023 . 13 July 2024.
  12. Web site: FDA Approves Atopic Dermatitis Label Expansion for Arcutis' Zoryve Cream . 13 July 2024 . BioSpace .
  13. Web site: Daxas 250 micrograms tablets - Summary of Product Characteristics (SmPC) . (emc) . 11 June 2020 . 28 September 2020 . 19 September 2020 . https://web.archive.org/web/20200919164902/https://www.medicines.org.uk/emc/product/9162/smpc . live .
  14. Web site: Daliresp : EPAR - Product Information. European Medicines Agency. Takeda GmbH. 26 September 2013. 18 November 2013. 26 June 2016. https://web.archive.org/web/20160626155812/http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002398/WC500103078.pdf. live.
  15. Web site: roflumilast (Rx) - Daliresp. Medscape Reference. WebMD. 18 November 2013. 12 September 2017. https://web.archive.org/web/20170912145935/http://reference.medscape.com/drug/daliresp-roflumilast-999626. live.
  16. Spina D . PDE4 inhibitors: current status . British Journal of Pharmacology . 155 . 3 . 308–15 . October 2008 . 18660825 . 2567892 . 10.1038/bjp.2008.307 .
  17. Web site: "Nycomed's Anti-Inflammatory Gains Approval in EU for COPD" . 10 July 2010 . 24 August 2017 . https://web.archive.org/web/20170824222207/http://www.genengnews.com/gen-news-highlights/nycomed-s-anti-inflammatory-gains-approval-in-eu-for-copd/81243622 . live .
  18. Web site: Drug Approval Package: Daliresp Tablets (roflumilast) NDA #022522 . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 28 September 2020 . 27 October 2020 . https://web.archive.org/web/20201027013611/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000TOC.cfm . live .
  19. FDA approves new drug to treat chronic obstructive pulmonary disease . 1 March 2011 . U.S. Food and Drug Administration (FDA) . 16 December 2019 . 18 January 2017 . https://web.archive.org/web/20170118091136/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm . dead .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Roflumilast".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.